Literature DB >> 27907271

Adult Attention-Deficit/Hyperactivity Disorder Diagnosis, Management, and Treatment in the DSM-5 Era.

Joel L Young1,2, David W Goodman3.   

Abstract

OBJECTIVE: To increase awareness of adult attention-deficit/hyperactivity disorder (ADHD) in the primary care community and to provide guidance for the management of this condition. Despite its increasing prevalence, adult ADHD largely remains underdiagnosed and inappropriately treated in the United States. The publication of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), has provided more clear diagnostic criteria for adult ADHD, but a solid framework supporting the transition of ADHD management from pediatric to adult primary care is lacking. DATA SOURCES: We searched PubMed and MEDLINE databases (January 1, 1984-June 1, 2016) using combinations of keywords, including ADHD, adult, diagnosis, prevalence, symptoms, treatment, comorbidity, compliance, and guidelines; international treatment guidelines; and the Diagnostic Interview for Adult ADHD websites to identify relevant clinical studies, reviews, meta-analyses, guidelines, and web-based resources describing updates to the DSM. STUDY SELECTION/DATA EXTRACTION: In total, 143 citations were selected based on their relevance to adult ADHD diagnosis, treatment, major issues, and practice guidelines.
RESULTS: The update on diagnostic criteria in the DSM-5 may increase the diagnosis of adult ADHD. There are critical differences between childhood and adult ADHD, and specific considerations should be taken with an adult ADHD diagnosis. Adult ADHD is primarily treated with pharmacotherapy assisted by behavior interventions. Caution should be exercised when using stimulants during pregnancy and the postpartum period. Adult ADHD patients often suffer from unemployment, financial difficulties, and an unsuccessful personal life. Adult-specific guidelines may improve adult ADHD treatment.
CONCLUSIONS: The successful diagnosis and management of adult ADHD require consideration of many facets including prior medical history and comorbid conditions and use of an individualized, evidence-based treatment approach. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27907271     DOI: 10.4088/PCC.16r02000

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN: 2155-7780


  7 in total

1.  Prescribing for ADHD in primary care.

Authors:  Ahmed Rashid; Nadia Llanwarne; Richard Lehman
Journal:  Br J Gen Pract       Date:  2018-04       Impact factor: 5.386

2.  Questionnaire-based computational screening of adult ADHD.

Authors:  Arthur Trognon; Manon Richard
Journal:  BMC Psychiatry       Date:  2022-06-15       Impact factor: 4.144

3.  Methylphenidate Use for Emotional Dysregulation in Children and Adolescents with ADHD and ADHD and ASD: A Naturalistic Study.

Authors:  Patrizia Ventura; Concetta de Giambattista; Paolo Trerotoli; Maddalena Cavone; Alessandra Di Gioia; Lucia Margari
Journal:  J Clin Med       Date:  2022-05-22       Impact factor: 4.964

4.  A survey of adult referrals to specialist attention-deficit/hyperactivity disorder clinics in Canada.

Authors:  Larry J Klassen; C Matthew Blackwood; Christopher J Reaume; Samuel Schaffer; James G Burns
Journal:  Int J Gen Med       Date:  2017-12-22

Review 5.  Convergence mechanism of mindfulness intervention in treating attention deficit hyperactivity disorder: Clues from current evidence.

Authors:  Xin-Peng Xu; Wei Wang; Song Wan; Chun-Feng Xiao
Journal:  World J Clin Cases       Date:  2022-09-16       Impact factor: 1.534

6.  Understanding ADHD: Toward an Innovative Therapeutic Intervention.

Authors:  Allyson Camp; Amanda Pastrano; Valeria Gomez; Kathleen Stephenson; William Delatte; Brianna Perez; Hunter Syas; Anthony Guiseppi-Elie
Journal:  Bioengineering (Basel)       Date:  2021-05-01

7.  The Association of Oral Stimulant Medication Adherence with Work Productivity among Adults with ADHD.

Authors:  William Spalding; Sepehr Farahbakhshian; Martine C Maculaitis; Eugenia Y Peck; Amir Goren
Journal:  J Atten Disord       Date:  2021-06-17       Impact factor: 3.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.